Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elvitegravir - Gilead Sciences

Next Previous
X
Search
Drug Profile

Elvitegravir - Gilead Sciences

Alternative Names: GS-9137; JTK-303; Vitekta

Latest Information Update: 05 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer Gilead Sciences; Japan Tobacco
  • Class Antiretrovirals; Quinolones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal HIV-1 infections

Most Recent Events

  • 03 Nov 2017 Gilead Sciences terminates a phase II/III trial in HIV-1 infections (Combination therapy, Treatment experienced, In adolescents, In children, In infants) in Italy, Germany, Spain, Thailand, South Africa, USA and Uganda (PO, tablets) (NCT01923311)
  • 27 Oct 2017 Gilead Sciences completes a phase II/III trial in HIV-1 infections (Combination therapy, Treatment experienced, In adolescents, In children, In infants) in Italy, Germany, Spain, Thailand, South Africa, USA and Uganda (PO, tablets) (NCT01923311)
  • 23 Aug 2017 No recent reports on development identified - Phase-III for HIV-1 infections (Combination therapy, Treatment-experienced) in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top